BNF for Children 2021-2022: September 2021-22

Product Information

The BNF for Children developed from the British National Formulary (BNF), which prior to 2005 had provided information on the treatment of children, with the doses largely determined by calculations based on the body weight of the child. This update contains 7 significant changes, 2 dose changes, 2 new monographs, 1 new preparation, and 1 deleted monograph. COVID-19 vaccine: update to Pfizer/BioNTech vaccine ( Comirnaty®) to include use in children from 6 months old.

Anon (1957). "The British National Formulary". British Medical Journal. 2 (5047): 758–759. PMC 1962234. PMID 13460381. Controlled drugs and drug dependence: updated guidance on prescription requirements for Schedule 2 and 3 Controlled Drugs. Aronson, J. K. (2004). "Drug interactions-information, education, and the British National Formulary". British Journal of Clinical Pharmacology. 57 (4): 371–372. doi: 10.1111/j.1365-2125.2004.02125.x. PMC 1884473. PMID 15025733. This update contains 4 significant changes, 1 dose change, 1 new preparation, 1 deleted monograph and 2 deleted preparations. It is used by pharmacists and doctors (both general practitioners (GPs) and generalist hospital practitioners, and by other prescribing healthcare professionals (such as nurses, pharmacy technicians, paramedics, and dentists); as a reference for correct dosage, indication, interactions and side effects of drugs. It is also used as a reassurance by those administering drugs, for example a nurse on a hospital ward, and even for patients and others seeking an authoritative source of advice on any aspect of pharmacotherapy.

Wade, O. L.; McDevitt, G. D. (1966). "Prescribing and the British National Formulary". British Medical Journal. 2 (5514): 635–637. doi: 10.1136/bmj.2.5514.635. PMC 1943465. PMID 20791099.

Elias-Jones, A.; Rylance, G. (2005). "The launch of the British National Formulary for Children". Archives of Disease in Childhood. 90 (10): 997–998. doi: 10.1136/adc.2005.080366. PMC 1720111. PMID 16177154. Adrenaline/epinephrine: recall of Emerade® 500 micrograms and Emerade® 300 micrograms auto-injectors, due to the potential for device failure [National Patient Safety Alert advice]. NICE apps for smartphones and tablets". www.nice.org.uk. National Institute for Health and Care Excellence. April 2014. Archived from the original on 13 August 2014 . Retrieved 19 July 2014.Quinolones: reminder of the risk of disabling and potentially long-lasting or irreversible side effects [MHRA/CHM advice] (see example in ciprofloxacin). Nitrofurantoin: reminder of the risks of pulmonary and hepatic adverse drug reactions [MHRA/CHM advice]. Non-steroidal anti-inflammatory drugs: potential risks following prolonged use after 20 weeks of pregnancy [MHRA/CHM advice]. This update contains 11 significant changes, 7 dose changes, 1 classification change, 3 new monographs, and 1 new preparation.